Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States

DOI: 10.1001/jamanetworkopen.2019.11952
JAMA Network Open, 2019, 2, e1911952.

#	Paper	IF	Citations
41	Using Machine Learning to Bend the Cost Curve-Addressing High-Cost Targeted Therapeutics. *JAMA Network Open*, **2019**, 2, e1911913	10.4	1
40	Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC. *Targeted Oncology*, **2019**, 14, 759-768	5	8
39	Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review. *PLoS ONE*, **2020**, 15, e0238536	3.7	11
38	Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer. *International Journal of Clinical Pharmacy*, **2020**, 42, 1175-1183	2.3	12
37	Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer. *Advances in Therapy*, **2020**, 37, 2116-2126	4.1	7
36	Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2020**, 80, 360-369	2	1
35	Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review. *Cancer Management and Research*, **2020**, 12, 4503-4518	3.6	3
34	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	11
33	Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis. *Japanese Journal of Clinical Oncology*, **2021**, 51, 778-785	2.8	0
32	Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US - updated analyses with additional trial follow-up. *Journal of Medical Economics*, **2021**, 24, 792-805	2.4	0
31	Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. *BMC Cancer*, **2021**, 21, 35	4.8	3
30	Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2021**, 21, 381-393	2.2	0
29	First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. *Cancers*, **2021**, 13,	6.6	6
28	Perspectivas da imunoterapia em pacientes com câncer de pulmão metastático. *Revista Científica Multidisciplinar Núcleo Do Conhecimento*, 62-83	0.2	
27	Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan. *Clinical Drug Investigation*, **2021**, 41, 381-389	3.2	0
26	First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2021**, 21, 1061-1067	2.2	9
25	Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US. *Frontiers in Public Health*, **2021**, 9, 650392	6	0

24	First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis. *Advances in Therapy*, **2021**, 38, 2447-2457	4.1	4
23	First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis. *Frontiers in Oncology*, **2021**, 11, 699781	5.3	4
22	Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives. *Annals of Translational Medicine*, **2021**, 9, 1481	3.2	0
21	First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis. *Oncologist*, **2021**, 26, e2013-e2020	5.7	2
20	Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review. *Pharmacoeconomics*, **2021**, 1	4.4	
19	A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer. *PharmacoEconomics - Open*, **2021**, 5, 365-383	2.1	1
18	NCAPH is negatively associated with Mcl-1 in non-small cell lung cancer. *Molecular Medicine Reports* , **2020**, 22, 2916-2924	2.9	2
17	In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer.. *Translational Cancer Research*, **2020**, 9, 1311-1318	0.3	
16	Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer. *PLoS ONE*, **2021**, 16, e0258605	3.7	1
15	Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma. *JAMA Network Open*, **2021**, 4, e2132262	10.4	0
14	Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression â□50.. *Frontiers in Pharmacology*, **2021**, 12, 803626	5.6	
13	The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study.		
12	First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.. *Frontiers in Pharmacology*, **2021**, 12, 788569	5.6	1
11	Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non-small cell carcinoma.. *Asia-Pacific Journal of Clinical Oncology*, **2022**,	1.9	
10	The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab.. *Frontiers in Oncology*, **2022**, 12, 857452	5.3	
9	Assessment of Treatment Strategies for Stage I Non-small Cell Lung Cancer in Patients with Comorbidities. *Lung Cancer*, **2022**,	5.9	0
8	Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. *Journal of Medical Economics*, **2022**, 25, 703-711	2.4	0
7	The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. 13,		0

6	Drug discovery of PD-L1 inhibitor Atezolizumab. 8, 660-667	
5	Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a costâ€effectiveness analysis. **2022**, 11, 1021-1030	0
4	The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study. **2022**, 17, e0263911	0
3	Atezolizumab versus Pembrolizumab for First-line Treatment in Non-small-cell Lung Cancer with High PD-L1 Expression: A Network Meta-analysis and Cost-effectiveness Analysis from Chinese Perspectives.	0
2	Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.	0
1	Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model. 11,	0